GlaxoSmithKline chief executive Andrew Witty will detail what action the drugmaker is taking in response to allegations of bribery against it in China when he presents quarterly results on Wednesday, sources said.

Chinese authorities are investigating GSK deals with travel agencies worth up to three billion yuan (€372 million) that they allege were used to facilitate bribes. The scale of the payments has fuelled debate as to whether GSK surveillance systems were good enough. – (Reuters)